（原标题：兴证全球基金减持泰格医药(03347)21.68万股 每股作价约37.7港元） 智通财经APP获悉，香港联交所最新资料显示，12月3日，兴证全球基金管理有限公司减持泰格医药 (03347)21.68万股，每股作价37.7041港元，总金额约为817.42万港元。减持后最新持股数目为603.35万 股，最新持股比例为4.9%。 ...

香港联交所最新资料显示，12月3日，兴证全球基金管理有限公司减持泰格医药（300347）(03347)21.68 万股，每股作价37.7041港元，总金额约为817.42万港元。减持后最新持股数目为603.35万股，最新持股 比例为4.9%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | 1 | RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | | 1 RMB | | 737,901,250 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | 1 | RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | | 1 RMB | | 737,901,250 ...

| 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 12.58% | 200.62 | -0.50% | 2432.40 | > 医药生物 | | sz000661 | 长春高新 | 4.87% | 98.98 | -1.11% | 403.78 | 医药生物 | | sz002252 | 十字典上 | 4.74% | 6.61 | -0.60% | 438.77 | 医药生物 | | sz300759 | 康龙化成 | 4.55% | 29.00 | -2.23% | 515.68 | 医药生物 | | sz300347 | 表格失药 | 4.54% | 48.80 | -3.88% | 420.18 | 医药生物 | | sz000021 | 深科技 | 4.16% | 23.98 | -2.56% | 376.89 | 电子 | | sz002714 | 牧原股份 | 3.62% | 49.13 | -1.15% | 2683.8 ...

Core Viewpoint - The Medical Health R Index (480016) closed at 7315.52 points, down 1.46%, with a trading volume of 16.103 billion yuan and a turnover rate of 0.53% on December 2 [1]. Group 1: Index Performance - Among the index constituents, 4 stocks rose while 46 stocks fell, with Jichuan Pharmaceutical leading the gainers at 1.0% and Tigermed leading the decliners at 3.88% [1]. - The total net outflow of main funds from the index constituents was 1.447 billion yuan, while retail investors saw a net inflow of 1.043 billion yuan [1]. Group 2: Top Constituents - The top ten constituents of the Medical Health R Index are as follows: - WuXi AppTec (13.66% weight, latest price 89.42, market cap 266.808 billion yuan, down 3.12%) [1] - Hengrui Medicine (11.00% weight, latest price 61.12, market cap 405.666 billion yuan, down 1.32%) [1] - Mindray Medical (7.57% weight, latest price 200.62, market cap 243.240 billion yuan, down 0.50%) [1] - United Imaging Healthcare (4.27% weight, latest price 128.71, market cap 106.077 billion yuan, down 1.97%) [1] - Pianzi Shou (3.48% weight, latest price 169.23, market cap 102.099 billion yuan, down 1.60%) [1] - Yierfu Technology (3.42% weight, latest price 11.50, market cap 107.242 billion yuan, down 0.60%) [1] - Kelun Pharmaceutical (2.59% weight, latest price 34.01, market cap 54.350 billion yuan, down 1.13%) [1] - Xinhecheng (2.42% weight, latest price 24.39, market cap 74.961 billion yuan, down 1.22%) [1] - Fosun Pharma (2.39% weight, latest price 27.09, market cap 72.342 billion yuan, down 0.88%) [1] - Ziji Shenzhou (2.27% weight, latest price 279.66, market cap 430.866 billion yuan, down 2.90%) [1]. Group 3: Fund Flow Details - The detailed fund flow for the index constituents shows that: - Mindray Medical had a main fund net inflow of 37.107 million yuan, while retail saw a net outflow of 4.2266 million yuan [2]. - Huatai Medical experienced a main fund net inflow of 16.9225 million yuan, with retail seeing a net outflow of 1.6967 million yuan [2]. - The overall trend indicates a mixed sentiment among different investor types, with main funds generally withdrawing while retail investors were net buyers [2]. Group 4: Recent Adjustments - In the last 10 days, the Medical Health R Index constituents underwent adjustments, adding 4 new stocks and removing 1 stock [2].

Core Insights - JPMorgan has reduced its stake in Tiger Medical (300347) by selling 831,247 shares at an average price of HKD 39.8240 per share, totaling approximately HKD 33.1036 million [1] - After the reduction, JPMorgan's remaining shareholding stands at approximately 9.5093 million shares, representing a holding percentage of 7.72% [1]

Core Viewpoint - JPMorgan has reduced its stake in Tiger Medical (03347) by selling 831,247 shares at an average price of HKD 39.8240 per share, totaling approximately HKD 33.1036 million, resulting in a new holding of about 9.5093 million shares, representing 7.72% of the company [1] Summary by Category - **Share Reduction Details** - JPMorgan sold 831,247 shares of Tiger Medical [1] - The average selling price was HKD 39.8240 per share [1] - The total amount from the sale was approximately HKD 33.1036 million [1] - **Post-Transaction Holdings** - After the reduction, JPMorgan's remaining shares in Tiger Medical are approximately 9.5093 million [1] - The new holding percentage is 7.72% [1]

Group 1 - JPMorgan Chase & Co. increased its stake in Tiger Medical (03347.HK) by purchasing 501,547 shares at an average price of HKD 38.9488 per share, totaling approximately HKD 19.535 million [1] - Following this transaction, JPMorgan's total holdings in Tiger Medical rose to 10,340,515 shares, increasing its ownership percentage from 7.99% to 8.39% [1]

Group 1 - JPMorgan increased its stake in Tiger Medical (300347) by 501,547 shares at a price of HKD 38.9488 per share, totaling approximately HKD 19.5347 million [1] - After the increase, JPMorgan's total shareholding in Tiger Medical is approximately 10.3405 million shares, representing a holding percentage of 8.39% [1]